Rani Therapeutics Holdings Inc. (RANI)
NASDAQ · Healthcare
Rani Therapeutics Holdings Inc. EBITDA 2020–2025
Rani Therapeutics Holdings Inc. annual/quarterly ebitda history and growth rate from 2021 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Rani Therapeutics Holdings Inc. ebitda for the quarter ending March 31, 2026 was -8.2 M, a 30.47% decrease year-over-year.
- Rani Therapeutics Holdings Inc. annual ebitda for 2025 was -37.4 M, a 28.45% decrease from 2024.
- Rani Therapeutics Holdings Inc. annual ebitda for 2024 was -52.3 M, a 19.90% decrease from 2023.
- Rani Therapeutics Holdings Inc. annual ebitda for 2023 was -65.3 M, a 3.77% increase from 2022.
- Rani Therapeutics Holdings Inc. annual ebitda for 2022 was -62.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Rani Therapeutics Holdings Inc. EBITDA — FAQ
Rani Therapeutics Holdings Inc. (RANI) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RANI's ebitda history?
The chart and table above show Rani Therapeutics Holdings Inc.'s ebitda by year and by quarter, including the growth rate.